FDA warns India’s Sun Pharma for violating manufacturing standards
India's largest drugmaker Sun Pharmaceutical Industries Ltd said it had received a warning letter from the U.S. Food and Drug Administration for violating manufacturing standards at its Halol plant in western India. The warning indicates the agency is not satisfied with the remedial measures Sun Pharma has been taking at the plant since last September when the FDA first highlighted issues at the plant after an inspection.
